Lyell Immunopharma
Company Type: Therapeutic development
Main focus: Developing CAR T-cell therapies to treat various cancers
Company stage: Clinical
Diseases: Aggressive B-cell Non-hodgkin lymphoma and other malignancies
Genome-editing tool: CRISPR-Cas9
Funding stage: Series C
Location: South San Francisco, California, USA
Website: lyell.com
Pipeline: lyell.com/our-pipeline
Partners:
Lyell Immunopharma is a clinical-stage biotechnology company focused on the development of CAR T-cell therapies to advance their use in cancer treatment. The company has developed multiple genetic and epigenetic T-cell reprogramming technologies to overcome limitations set by current cell therapies. These involve genetically engineering T cells using CRISPR-Cas9 technology to target c-Jun overexpression and knockout of NR4A3. Lyell’s proprietary epigenetic reprogramming platforms, Epi-R™ and Stim-R™, aim to enhance T-cell mediated anti-tumour activity through epigenetic editing of T-cell therapeutics.